Session Information

Invited Symposium

[IS-FR-104] Angiogenesis
Go back
print
Day
Apr 04 (Fri)
Time
13:30 - 15:00
Room
Room 6 - Tokyo International Forum 5F Hall D5
Topic
Pharmacology, Ocular Drug Delivery
Chair/Coordinator
Chair)Mark Gillies、Chair)Barry Kupperman
Description
A special session dedicated to angiogenesis, which is an out-of-ordinary physiologic process, especially from the ophthalmologists' perspective. Regarded as the most-wanted villain for its underlying and mediating role in AMD and other retinal pathologies, angiogenesis has become the target of choice in the medical treatment of these diseases. Beside news and updates on antiangiogenic treatment, the audience is challenged to share the dilemmas and still-unanswered questions.

Duration 15min (including Q&A), Panel Discussion = 0min

IS-FR-104-1 / 

Pharmacology, Ocular Drug Delivery

The CSC, Type 1 Neovascularization, and PCV Connection

K. Bailey Freund

The CSC, Type 1 Neovascularization, and PCV Connection

Duration 15min (including Q&A), Panel Discussion = 0min

IS-FR-104-2 / 

Pharmacology, Ocular Drug Delivery

Current Anti-VEGF Therapies for NVAMD in Clinical Trials vs. Real Life

Francesco Bandello

Current Anti-VEGF Therapies for NVAMD in Clinical Trials vs. Real Life

Duration 15min (including Q&A), Panel Discussion = 0min

IS-FR-104-3 / 

Pharmacology, Ocular Drug Delivery

VEGF Antagonists – Can We Give too Much?

Dov Weinberger

VEGF Antagonists – Can We Give too Much?

Duration 15min (including Q&A), Panel Discussion = 0min

Cancelled / 

Pharmacology, Ocular Drug Delivery

The Impact of Neutralizing Ab's Against Anti-VEGF Ab

The Impact of Neutralizing Ab's Against Anti-VEGF Ab

Duration 15min (including Q&A), Panel Discussion = 0min

IS-FR-104-5 / 

Pharmacology, Ocular Drug Delivery

Stem Cell Trials in Antiangiogenic Diseases

David Pelayes

Stem Cell Trials in Antiangiogenic Diseases

Duration 15min (including Q&A), Panel Discussion = 0min

IS-FR-104-6 / 

Pharmacology, Ocular Drug Delivery

Anti-VEGF DARP in for Wet AMD

Mark Gillies

Anti-VEGF DARP in for Wet AMD

Go back